Christopher C Gibson1, Weiquan Zhu1, Chadwick T Davis1, Jay A Bowman-Kirigin1, Aubrey C Chan1, Jing Ling1, Ashley E Walker1, Luca Goitre1, Simona Delle Monache1, Saverio Francesco Retta1, Yan-Ting E Shiu1, Allie H Grossmann1, Kirk R Thomas1, Anthony J Donato1, Lisa A Lesniewski1, Kevin J Whitehead1, Dean Y Li2. 1. From the Program in Molecular Medicine (C.C.G., W.Z., C.T.D., J.A.B.-K., A.C.C., J.L., A.H.G., K.R.T., K.J.W., D.Y.L.), Department of Bioengineering (C.C.G., Y.-T.E.S.), Department of Medicine (C.C.G., W.Z., K.R.T., D.Y.L.), Department of Human Genetics (C.T.D.), Department of Oncological Sciences (A.C.C., D.Y.L.), Division of Geriatrics, Department of Medicine (A.E.W., A.J.D., L.A.L.), Division of Nephrology and Hypertension, Department of Medicine (Y.-T.E.S.), Department of Pathology (A.H.G.), Division of Cardiology, and Department of Medicine (K.J.W., D.Y.L.), University of Utah, Salt Lake City, UT; Recursion Pharmaceuticals, LLC, Salt Lake City, UT (C.C.G., D.Y.L.); CCM Italia, Department of Clinical and Biological Sciences, University of Torino, Orbassano, Torino, Italy (L.G., S.F.R.); CCM Italia, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy (S.D.M.); Geriatrics Research Education and Clinical Center, Veteran's Affairs Medical Center, Salt Lake City, UT (A.J.D., L.A.L.); The Key Laboratory for Human Disease Gene Study of Sichuan Province, Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China (D.Y.L.); and Cardiology Section, VA Salt Lake City Health Care System, Salt Lake City, UT (K.J.W., O.Y.L.). 2. From the Program in Molecular Medicine (C.C.G., W.Z., C.T.D., J.A.B.-K., A.C.C., J.L., A.H.G., K.R.T., K.J.W., D.Y.L.), Department of Bioengineering (C.C.G., Y.-T.E.S.), Department of Medicine (C.C.G., W.Z., K.R.T., D.Y.L.), Department of Human Genetics (C.T.D.), Department of Oncological Sciences (A.C.C., D.Y.L.), Division of Geriatrics, Department of Medicine (A.E.W., A.J.D., L.A.L.), Division of Nephrology and Hypertension, Department of Medicine (Y.-T.E.S.), Department of Pathology (A.H.G.), Division of Cardiology, and Department of Medicine (K.J.W., D.Y.L.), University of Utah, Salt Lake City, UT; Recursion Pharmaceuticals, LLC, Salt Lake City, UT (C.C.G., D.Y.L.); CCM Italia, Department of Clinical and Biological Sciences, University of Torino, Orbassano, Torino, Italy (L.G., S.F.R.); CCM Italia, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy (S.D.M.); Geriatrics Research Education and Clinical Center, Veteran's Affairs Medical Center, Salt Lake City, UT (A.J.D., L.A.L.); The Key Laboratory for Human Disease Gene Study of Sichuan Province, Institute of Laboratory Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Chengdu, Sichuan, China (D.Y.L.); and Cardiology Section, VA Salt Lake City Health Care System, Salt Lake City, UT (K.J.W., O.Y.L.). dean.li@u2m2.utah.edu.
Abstract
BACKGROUND: Cerebral cavernous malformation (CCM) is a hemorrhagic stroke disease affecting up to 0.5% of North Americans that has no approved nonsurgical treatment. A subset of patients have a hereditary form of the disease due primarily to loss-of-function mutations in KRIT1, CCM2, or PDCD10. We sought to identify known drugs that could be repurposed to treat CCM. METHODS AND RESULTS: We developed an unbiased screening platform based on both cellular and animal models of loss of function of CCM2. Our discovery strategy consisted of 4 steps: an automated immunofluorescence and machine-learning-based primary screen of structural phenotypes in human endothelial cells deficient in CCM2, a secondary screen of functional changes in endothelial stability in these same cells, a rapid in vivo tertiary screen of dermal microvascular leak in mice lacking endothelial Ccm2, and finally a quaternary screen of CCM lesion burden in these same mice. We screened 2100 known drugs and bioactive compounds and identified 2 candidates, cholecalciferol (vitamin D3) and tempol (a scavenger of superoxide), for further study. Each drug decreased lesion burden in a mouse model of CCM vascular disease by ≈50%. CONCLUSIONS: By identifying known drugs as potential therapeutics for CCM, we have decreased the time, cost, and risk of bringing treatments to patients. Each drug also prompts additional exploration of biomarkers of CCM disease. We further suggest that the structure-function screening platform presented here may be adapted and scaled to facilitate drug discovery for diverse loss-of-function genetic vascular disease.
BACKGROUND:Cerebral cavernous malformation (CCM) is a hemorrhagic stroke disease affecting up to 0.5% of North Americans that has no approved nonsurgical treatment. A subset of patients have a hereditary form of the disease due primarily to loss-of-function mutations in KRIT1, CCM2, or PDCD10. We sought to identify known drugs that could be repurposed to treat CCM. METHODS AND RESULTS: We developed an unbiased screening platform based on both cellular and animal models of loss of function of CCM2. Our discovery strategy consisted of 4 steps: an automated immunofluorescence and machine-learning-based primary screen of structural phenotypes in human endothelial cells deficient in CCM2, a secondary screen of functional changes in endothelial stability in these same cells, a rapid in vivo tertiary screen of dermal microvascular leak in mice lacking endothelial Ccm2, and finally a quaternary screen of CCM lesion burden in these same mice. We screened 2100 known drugs and bioactive compounds and identified 2 candidates, cholecalciferol (vitamin D3) and tempol (a scavenger of superoxide), for further study. Each drug decreased lesion burden in a mouse model of CCM vascular disease by ≈50%. CONCLUSIONS: By identifying known drugs as potential therapeutics for CCM, we have decreased the time, cost, and risk of bringing treatments to patients. Each drug also prompts additional exploration of biomarkers of CCM disease. We further suggest that the structure-function screening platform presented here may be adapted and scaled to facilitate drug discovery for diverse loss-of-function genetic vascular disease.
Authors: T Sahoo; E W Johnson; J W Thomas; P M Kuehl; T L Jones; C G Dokken; J W Touchman; C J Gallione; S Q Lee-Lin; B Kosofsky; J H Kurth; D N Louis; G Mettler; L Morrison; A Gil-Nagel; S S Rich; J M Zabramski; M S Boguski; E D Green; D A Marchuk Journal: Hum Mol Genet Date: 1999-11 Impact factor: 6.150
Authors: David A McDonald; Robert Shenkar; Changbin Shi; Rebecca A Stockton; Amy L Akers; Melanie H Kucherlapati; Raju Kucherlapati; James Brainer; Mark H Ginsberg; Issam A Awad; Douglas A Marchuk Journal: Hum Mol Genet Date: 2010-10-11 Impact factor: 6.150
Authors: Christina L Liquori; Michel J Berg; Ferdinando Squitieri; Tracey P Leedom; Louis Ptacek; Eric W Johnson; Douglas A Marchuk Journal: Am J Hum Genet Date: 2006-11-14 Impact factor: 11.025
Authors: Tara M Mleynek; Aubrey C Chan; Michael Redd; Christopher C Gibson; Chadwick T Davis; Dallas S Shi; Tiehua Chen; Kandis L Carter; Jing Ling; Raquel Blanco; Holger Gerhardt; Kevin Whitehead; Dean Y Li Journal: Hum Mol Genet Date: 2014-07-02 Impact factor: 6.150
Authors: Amy L Akers; Eric Johnson; Gary K Steinberg; Joseph M Zabramski; Douglas A Marchuk Journal: Hum Mol Genet Date: 2008-12-16 Impact factor: 6.150
Authors: C Denier; S Goutagny; P Labauge; V Krivosic; M Arnoult; A Cousin; A L Benabid; J Comoy; P Frerebeau; B Gilbert; J P Houtteville; M Jan; F Lapierre; H Loiseau; P Menei; P Mercier; J J Moreau; A Nivelon-Chevallier; F Parker; A M Redondo; J M Scarabin; M Tremoulet; M Zerah; J Maciazek; E Tournier-Lasserve Journal: Am J Hum Genet Date: 2004-01-22 Impact factor: 11.025
Authors: Kevin J Whitehead; Aubrey C Chan; Sutip Navankasattusas; Wonshill Koh; Nyall R London; Jing Ling; Anne H Mayo; Stavros G Drakos; Christopher A Jones; Weiquan Zhu; Douglas A Marchuk; George E Davis; Dean Y Li Journal: Nat Med Date: 2009-01-18 Impact factor: 53.440
Authors: Carol L Wagner; Bruce W Hollis; Kalliopi Kotsa; Hana Fakhoury; Spyridon N Karras Journal: Rev Endocr Metab Disord Date: 2017-09 Impact factor: 6.514
Authors: Sayoko Nishimura; Ketu Mishra-Gorur; JinSeok Park; Yulia V Surovtseva; Said M Sebti; Andre Levchenko; Angeliki Louvi; Murat Gunel Journal: Proc Natl Acad Sci U S A Date: 2017-05-12 Impact factor: 11.205
Authors: Romuald Girard; Maged D Fam; Hussein A Zeineddine; Huan Tan; Abdul Ghani Mikati; Changbin Shi; Michael Jesselson; Robert Shenkar; Meijing Wu; Ying Cao; Nicholas Hobson; Henrik B W Larsson; Gregory A Christoforidis; Issam A Awad Journal: J Neurosurg Date: 2016-08-05 Impact factor: 5.115
Authors: Mark-Anthony Bray; Shantanu Singh; Han Han; Chadwick T Davis; Blake Borgeson; Cathy Hartland; Maria Kost-Alimova; Sigrun M Gustafsdottir; Christopher C Gibson; Anne E Carpenter Journal: Nat Protoc Date: 2016-08-25 Impact factor: 13.491
Authors: Romuald Girard; Hussein A Zeineddine; Courtney Orsbon; Huan Tan; Thomas Moore; Nick Hobson; Robert Shenkar; Rhonda Lightle; Changbin Shi; Maged D Fam; Ying Cao; Le Shen; April I Neander; Autumn Rorrer; Carol Gallione; Alan T Tang; Mark L Kahn; Douglas A Marchuk; Zhe-Xi Luo; Issam A Awad Journal: J Neurosci Methods Date: 2016-06-23 Impact factor: 2.390